Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Orphai Therapeutics Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is located in 1 distinct art unit, reflecting the technical focus for the company's current patenting efforts. Such a distribution suggests a targeted strategy for their intellectual property development. The concentration in 1 distinct art unit allows for a specialized approach to the unique examination challenges of the Biotechnology & Pharmaceuticals sector.
The company's pending application is managed by 1 distinct examiner, ensuring a singular point of contact at the patent office. GULLEDGE, BRIAN M is the busiest examiner, currently responsible for 1 busiest examiner pending action. Since this examiner is the only one reviewing the company's pending work, the immediate trajectory of their portfolio depends on the specific feedback and requirements of this individual. Effectively addressing the 1 pending office action with this examiner is essential for the company's current prosecution success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GULLEDGE, BRIAN M | 1 | 55.8% | +26.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18643988 | INHALABLE RAPAMYCIN FORMULATION FOR TREATING AGE-RELATED CONDITIONS | GULLEDGE, BRIAN M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18643988 | INHALABLE RAPAMYCIN FORMULATION FOR TREATING AGE-RELATED CONDITIONS | GULLEDGE, BRIAN M | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18643988 | INHALABLE RAPAMYCIN FORMULATION FOR TREATING AGE-RELATED CONDITIONS | GULLEDGE, BRIAN M | 1699 | §103§112 | Final Rejection | — | Pending | Apr 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial